Stifel Financial Corp Buys 23,283 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Stifel Financial Corp boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 54.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,391 shares of the company's stock after purchasing an additional 23,283 shares during the quarter. Stifel Financial Corp's holdings in Teva Pharmaceutical Industries were worth $1,196,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Thrivent Financial for Lutherans lifted its holdings in Teva Pharmaceutical Industries by 21.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company's stock worth $4,046,000 after purchasing an additional 40,218 shares during the last quarter. Sio Capital Management LLC bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $24,314,000. Charles Schwab Investment Management Inc. grew its stake in shares of Teva Pharmaceutical Industries by 24.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 899,175 shares of the company's stock valued at $16,203,000 after acquiring an additional 177,836 shares in the last quarter. Pitcairn Co. bought a new position in Teva Pharmaceutical Industries during the third quarter worth about $947,000. Finally, Coronation Fund Managers Ltd. bought a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $1,334,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company's stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.55% of the company's stock.

Analysts Set New Price Targets

TEVA has been the topic of several recent research reports. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Monday, October 21st. Barclays raised their price objective on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 18th. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a "buy" rating in a research report on Tuesday, September 3rd. Finally, StockNews.com cut Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $20.88.

Teva Pharmaceutical Industries Price Performance

TEVA traded up $0.12 on Monday, reaching $22.21. The stock had a trading volume of 11,771,780 shares, compared to its average volume of 9,456,189. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a market capitalization of $25.16 billion, a price-to-earnings ratio of -26.13, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.34 and a fifty-two week high of $22.25. The firm has a 50-day moving average of $17.89 and a 200-day moving average of $17.56.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.